This is a branding and product relaunch with no financial data. Monitor the next quarterly earnings release for any impact on revenue trends or coach network metrics. The stock has a history of negative drift following neutral filings, so no immediate catalyst is present.
Price Chart
Executive Summary
Medifast announced the rebranding of its OPTAVIA lifestyle brand to Trilivy, a comprehensive metabolic health system, on July 17, 2026. The press release introduces new product formulations and clinical claims but contains no financial data, guidance, or preliminary results. This is a marketing/branding event with no immediate quantifiable impact on revenue or earnings.
Key Facts
- Medifast rebranded its OPTAVIA subsidiary to Trilivy, described as a comprehensive metabolic health system.
- The launch includes newly formulated meal replacements (Trilivy Reset Fueling line) with MetaVantage Technology.
- No financial data, guidance updates, or preliminary results were provided in the filing.
- The press release cites clinical study results: 14% reduction in visceral fat in 16 weeks and 98% lean mass preservation.
- Newly formulated meal replacements are planned to debut in August 2026.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- Rebranding may not translate to improved sales or coach recruitment.
- Transition costs or supply chain disruptions for new product formulations are not disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-048574 |
| Document: 0001628280-26-048574-index-headers.html | 0001628280-26-048574 |
| Document: 0001628280-26-048574-index.html | 0001628280-26-048574 |
| Document: 0001628280-26-048574.txt | 0001628280-26-048574 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $12.11 | awaiting T+5 | — | $12.49 (+3.14%) |
Oct 15, 2026 12d ago | Press Release | $12.06 $12.17 | ▲ +0.91% | ▲ +1.93% | $12.49 (+3.57%) |
Oct 6, 2026 21d ago | Press Release | $11.51 $11.67 | ▲ +1.39% | ▲ +1.53% | $12.49 (+8.51%) |
Oct 1, 2026 26d ago | Press Release | $11.43 $11.43 | · 0.00% | ▼ −1.30% | $12.49 (+9.27%) |
Aug 28, 2026 8w ago | Insider Buy | $12.18 $12.63 | ▲ +3.69% | ▲ +3.59% | $12.49 (+2.55%) |
Aug 26, 2026 8w ago | Insider Buy | $12.22 $12.67 | ▲ +3.68% | ▲ +3.80% | $12.49 (+2.21%) |
Aug 21, 2026 9w ago | Insider Buy | $11.95 $12.18 | ▲ +1.92% | ▲ +1.45% | $12.49 (+4.52%) |
Jul 17, 2026 14w ago | 8-K | $10.26 $9.45 | ▼ −7.89% | ▼ −7.21% | $12.49 (+21.73%) |
Jun 1, 2026 21w ago | 8-K | $12.70 $12.10 | ▼ −4.72% | ▼ −1.97% | $12.49 (−1.65%) |
May 26, 2026 22w ago | 8-K | $12.72 $12.36 | ▼ −2.83% | ▼ −4.04% | $12.49 (−1.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers